[Experience with cefmetazole in the urological fields]. 1982

A Tajima, and Y Ohmi, and H Masuda, and T Ushiyama, and K Fujii, and M Hata, and N Ohta, and K Suzuki, and K Fujita, and Y Aso

Recently, a new antibiotic of cephamycins, cefmetazole (CMZ) has been developed. In our clinic, CMZ was used to examine its clinical effect and adverse reactions, and the results were herein reported. The CMZ was administered to 8 patients for the prevention of postoperative infections, 7 with genitourinary infections and 1 with maxillitis complicated with uremia. For these patients, a daily dose of 1 to 6 g of CMZ was intravenously given for a period of 4 to 12 days. Among the 8 patients who received CMZ for the prevention of postoperative infections, there were 1 case with urinary tract infection, 1 with wound infection and 2 with fever of over 38 degrees C, but they had no serious infections. In the clinical observations on 3 cases with pyelonephritis, the CMZ showed marked effectiveness in 2 cases and effectiveness in 1 case. It must be noted that CMZ was proved to be markedly effective for pyelonephritis caused by Serratia marcescens. In the cases with acute epididymitis and prostatitis, a good effect of CMZ was obtained. Similarly in the case with maxillitis complicated with uremia, the maxillitis was improved by the effect of CMZ and hemodialysis. No cases with hepatic or renal dysfunction were observed after using CMZ. It is concluded that satisfactory effect of CMZ was obtained clinically.

UI MeSH Term Description Entries
D007275 Injections, Intravenous Injections made into a vein for therapeutic or experimental purposes. Intravenous Injections,Injection, Intravenous,Intravenous Injection
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011183 Postoperative Complications Pathologic processes that affect patients after a surgical procedure. They may or may not be related to the disease for which the surgery was done, and they may or may not be direct results of the surgery. Complication, Postoperative,Complications, Postoperative,Postoperative Complication
D002511 Cephalosporins A group of broad-spectrum antibiotics first isolated from the Mediterranean fungus ACREMONIUM. They contain the beta-lactam moiety thia-azabicyclo-octenecarboxylic acid also called 7-aminocephalosporanic acid. Antibiotics, Cephalosporin,Cephalosporanic Acid,Cephalosporin,Cephalosporin Antibiotic,Cephalosporanic Acids,Acid, Cephalosporanic,Acids, Cephalosporanic,Antibiotic, Cephalosporin,Cephalosporin Antibiotics
D002513 Cephamycins Naturally occurring family of beta-lactam cephalosporin-type antibiotics having a 7-methoxy group and possessing marked resistance to the action of beta-lactamases from gram-positive and gram-negative organisms. Antibiotics, Cephamycin,Cephamycin,Cephamycin Antibiotics
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths

Related Publications

A Tajima, and Y Ohmi, and H Masuda, and T Ushiyama, and K Fujii, and M Hata, and N Ohta, and K Suzuki, and K Fujita, and Y Aso
April 1983, Hinyokika kiyo. Acta urologica Japonica,
A Tajima, and Y Ohmi, and H Masuda, and T Ushiyama, and K Fujii, and M Hata, and N Ohta, and K Suzuki, and K Fujita, and Y Aso
January 1984, Hinyokika kiyo. Acta urologica Japonica,
A Tajima, and Y Ohmi, and H Masuda, and T Ushiyama, and K Fujii, and M Hata, and N Ohta, and K Suzuki, and K Fujita, and Y Aso
May 1979, The Japanese journal of antibiotics,
A Tajima, and Y Ohmi, and H Masuda, and T Ushiyama, and K Fujii, and M Hata, and N Ohta, and K Suzuki, and K Fujita, and Y Aso
January 1990, La Clinica terapeutica,
A Tajima, and Y Ohmi, and H Masuda, and T Ushiyama, and K Fujii, and M Hata, and N Ohta, and K Suzuki, and K Fujita, and Y Aso
January 1983, The Japanese journal of antibiotics,
A Tajima, and Y Ohmi, and H Masuda, and T Ushiyama, and K Fujii, and M Hata, and N Ohta, and K Suzuki, and K Fujita, and Y Aso
April 1989, The Journal of antimicrobial chemotherapy,
A Tajima, and Y Ohmi, and H Masuda, and T Ushiyama, and K Fujii, and M Hata, and N Ohta, and K Suzuki, and K Fujita, and Y Aso
June 1954, Therapie der Gegenwart,
A Tajima, and Y Ohmi, and H Masuda, and T Ushiyama, and K Fujii, and M Hata, and N Ohta, and K Suzuki, and K Fujita, and Y Aso
March 1982, The Japanese journal of antibiotics,
A Tajima, and Y Ohmi, and H Masuda, and T Ushiyama, and K Fujii, and M Hata, and N Ohta, and K Suzuki, and K Fujita, and Y Aso
April 1965, The Journal of antibiotics. Ser. B,
A Tajima, and Y Ohmi, and H Masuda, and T Ushiyama, and K Fujii, and M Hata, and N Ohta, and K Suzuki, and K Fujita, and Y Aso
June 1968, The Japanese journal of antibiotics,
Copied contents to your clipboard!